Labo Euromedis Valuation Multiples

Discover revenue and EBITDA valuation multiples for Labo Euromedis and similar public comparables like Inspira Technologies, Geratherm Medical, Scandinavian Real Heart, Iridex and more.

Labo Euromedis Overview

About Labo Euromedis

Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.


Founded

1996

HQ

France

Employees

21

Financials (FY)

Revenue: $47M
EBITDA: $1M

EV

$5M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Labo Euromedis Financials

Labo Euromedis reported last fiscal year revenue of $47M and EBITDA of $1M.

In the same fiscal year, Labo Euromedis generated $5M in gross profit, $1M in EBITDA, and had net loss of ($151K).

Revenue (LTM)


Labo Euromedis P&L

In the most recent fiscal year, Labo Euromedis reported revenue of $47M and EBITDA of $1M.

Labo Euromedis is unprofitable as of last fiscal year, with gross margin of 11%, EBITDA margin of 2%, and net margin of (0%).

See analyst estimates for Labo Euromedis
Last FY202320242025202620272028
Revenue$47M$39M$41M$47M
Gross Profit$5M$208K$2M$5M
Gross Margin11%1%5%11%
EBITDA$1M$25M$1M$1M
EBITDA Margin2%65%2%2%
EBIT Margin2%(13%)4%2%
Net Profit($151K)$15M($7M)($151K)
Net Margin(0%)39%(17%)(0%)

Financial data powered by Morningstar, Inc.

Labo Euromedis Stock Performance

Labo Euromedis has current market cap of $17M, and enterprise value of $5M.

Market Cap Evolution


Labo Euromedis' stock price is $5.89.

Labo Euromedis share price increased by 2.2% in the last 30 days, and by 16.8% in the last year.

Labo Euromedis has an EPS (earnings per share) of $-0.05.

See more trading valuation data for Labo Euromedis
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$5M$17M5.1%2.2%7.8%16.8%$-0.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Labo Euromedis Valuation Multiples

Labo Euromedis trades at 0.1x EV/Revenue multiple, and 4.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Labo Euromedis

EV / Revenue (LTM)


Labo Euromedis Financial Valuation Multiples

As of July 19, 2026, Labo Euromedis has market cap of $17M and EV of $5M.

Labo Euromedis has a P/E ratio of (111.6x).

Last FY202320242025202620272028
EV/Revenue0.1x0.1x0.1x0.1x
EV/EBITDA4.6x0.2x4.7x4.6x
EV/EBIT6.3x(1.0x)3.2x6.3x
EV/Gross Profit0.9x22.8x2.2x0.9x
P/E(111.6x)1.1x(2.4x)(111.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Labo Euromedis Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Labo Euromedis Margins & Growth Rates

Labo Euromedis decreased revenue by 1% but EBITDA grew by 106% in the last fiscal year.

In the most recent fiscal year, Labo Euromedis reported gross margin of 11%, EBITDA margin of 2%, and net margin of (0%).

See estimated margins and future growth rates for Labo Euromedis

Labo Euromedis Margins

Last FY202420252026202720282029
Gross Margin11%5%11%-
EBITDA Margin2%2%2%5%
EBIT Margin2%4%2%3%
Net Margin(0%)(17%)(0%)4%
FCF Margin---3%

Labo Euromedis Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(1%)6%13%(1%)
Gross Profit Growth-960%129%-
EBITDA Growth106%(96%)3%106%
EBIT Growth87%(131%)(50%)87%
Net Profit Growth(1270%)(147%)(98%)(1270%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Labo Euromedis Operational KPIs

Labo Euromedis' revenue per employee in the last FY averaged $2.2M, while opex per employee averaged $0.2M for the same period.

Labo Euromedis' Rule of 40 is 3% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Labo Euromedis' Rule of X is 2% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Labo Euromedis
Last FY202320242025202620272028
Rule of 403%---
Bessemer Rule of X2%---
Revenue per Employee$2.2M---
Opex per Employee$0.2M---
Opex to Revenue9%13%2%9%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Labo Euromedis Competitors

Labo Euromedis competitors include Inspira Technologies, Geratherm Medical, Scandinavian Real Heart, Iridex, Renalytix, Modular Medical, Accrelist, Impedimed, Genematrix and Biosynex.

Most Labo Euromedis public comparables operate across Medical Devices and Wholesale Distribution.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Inspira Technologies-0.5x-(13.4x)
Geratherm Medical0.5x0.5x6.3x5.8x
Scandinavian Real Heart--(4.2x)-
Iridex0.4x0.4x8.9x11.8x
Renalytix5.3x-(0.7x)-
Modular Medical--(0.4x)-
Accrelist1.2x-42.0x-
Impedimed1.9x1.6x(1.5x)(1.6x)

This data is available for Pro users. Sign up to see all Labo Euromedis competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Labo Euromedis

When was Labo Euromedis founded?Labo Euromedis was founded in 1996.
Where is Labo Euromedis headquartered?Labo Euromedis is headquartered in France.
How many employees does Labo Euromedis have?As of today, Labo Euromedis has over 21 employees.
Is Labo Euromedis publicly listed?Yes, Labo Euromedis is a public company listed on Euronext Paris.
What is the stock symbol of Labo Euromedis?Labo Euromedis trades under ALEMG ticker.
When did Labo Euromedis go public?Labo Euromedis went public in 2000.
Who are competitors of Labo Euromedis?Labo Euromedis main competitors include Inspira Technologies, Geratherm Medical, Scandinavian Real Heart, Iridex, Renalytix, Modular Medical, Accrelist, Impedimed, Genematrix, Biosynex.
What is the current market cap of Labo Euromedis?Labo Euromedis' current market cap is $17M.
What is the current revenue of Labo Euromedis?Labo Euromedis' last fiscal year revenue is $47M.
What is the current revenue growth of Labo Euromedis?Labo Euromedis revenue growth (vs. last FY) is (1%).
What is the current EV/Revenue multiple of Labo Euromedis?Current revenue multiple of Labo Euromedis is 0.1x.
Is Labo Euromedis profitable?No, Labo Euromedis is not profitable.
How many companies Labo Euromedis has acquired to date?Labo Euromedis hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Labo Euromedis has invested to date?Labo Euromedis hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Labo Euromedis

Lists including Labo Euromedis

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial